CYP1A2 and hepatocellular carcinoma: Additionally, subcutaneous xenograft models suggested the increased tumorigenicity (Figure 3G) and up-regulated MET and MMPs expression in xenograft tumors formed by CYP1A2-deficient HCC cells (Figure 3H).